Stevens-Johnson Syndrome Associated to the Administration of Janssen AD26.COV2.S COVID-19 Vaccine in Tijuana, Baja California, México, a Case Report

Daniel Pacheco Ambriz; Lorena Lizbeth Félix Guerrero; Giselle Anahí Olivas Cárdenas; Alicia Pastora Amarillas Villalvazo; Lorena Diaz Amezquita

doi:doi:10.11648/j.ijcoms.20220801.11

Stevens-Johnson Syndrome Associated to the Administration of Janssen AD26.COV2.S COVID-19 Vaccine in Tijuana, Baja California, México, a Case Report

Daniel Pacheco Ambriz, Lorena Lizbeth Félix Guerrero, Giselle Anahí Olivas Cárdenas, Alicia Pastora Amarillas Villalvazo, Lorena Diaz Amezquita

Published in International Journal of Clinical Oral and Maxillofacial Surgery (Volume 8, Issue 1)

Received: 10 November 2021 Accepted: 7 December 2021 Published: 24 January 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: Stevens-Johnson syndrome and toxic epidermal necrolysis are rare pathologies characterized by mucocutaneous involvement, considered as late hypersensitivity mainly associated with drugs. Other less frequent causes include infections, vaccines, systemic diseases and botanical medicine. COVID-19 vaccines can cause adverse reactions mainly from vaccine- induced immune responses. We present a clinical case of a patient with Stevens-Johnson syndrome diagnose, without no history of factors related to this pathology, except for the use of Ad26.COV2.S (Janssen/Johnson & Johnson) vaccine Clinical case: A 20 years old male patient with clinical and histopathological characteristics compatible with Stevens Johnson syndrome and whose background history was the application of the Ad26.COV2.S vaccine (Janssen / Johnson & Johnson) 11 days prior to the start of the disease. At arrival at the emergency room he got a dermatologic consult who started treatment with metilprednisolone 1gr intravenously, Aciclovir 200mg orally and topic fluocinolone. He was hospitalized in charge of dermatology presenting improvement deciding outpatient treatment. Five days after his hospital discharge, at dermatology external consultation he´s found with overall improvement and fewer dermic lesions. Conclusions: At this time we didn’t find a case where they reported Stevens-Johnson syndrome associated to Ad26.COV2.S vaccine. Although the information regarding the adverse effects of the new vaccines against COVID-19 is still limited, there is the possibility of a direct association between the Ad26.COV2.S vaccine and a Stevens Johnson Syndrome.

Published in	International Journal of Clinical Oral and Maxillofacial Surgery (Volume 8, Issue 1)
DOI	10.11648/j.ijcoms.20220801.11
Page(s)	1-4
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Stevens Johnson Syndrome, Toxic Epidermal Necrolysis, COVID-19, Ad26.COV2.S Vaccine

References

[1]	Charlton OA, Harris V, Phan K, et al. Toxic Epidermal Necrolysis and Steven-Johnson Syndrome: A Comprehensive Review. Adv Wound Care (New Rochelle). 2020; 9 (7): 426-439. doi: 10.1089/wound.2019.0977.
[2]	Lavery MJ, Nawimana S, Parslew R, Stewart L. A flare of pre- existing erythema multiforme following BNT162b2 (Pfizer- BioNTech) COVID-19 vaccine. Clin Exp Dermatol. 2021; 46: 1325-1327. doi: 10.1111/ced.14714.
[3]	Salazar Mayorga et al. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, a diagnostic and therapeutic. Synergy Medical Journal. Vol. 5. Num. 1. January 2020, e308.
[4]	Kim MA, Lee YW, Kim SR, et al. COVID-19 vaccine-associated anaphylaxis and allergic reactions: consensus statements of the KAAACI Urticaria/Angioedema/ Anaphy-laxis Working Group. Allergy Asthma Immunol Res. 2021; 13: 526-544. doi: 10.4168/aair.2021.13.4.526.
[5]	Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, et al. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Clin Rev Allergy Immunol. 2018; 54 (1): 147-176. doi: 10.1007/s12016-017-8654-z.
[6]	CDC COVID 19 Response Team. Food and Drug Admin-istration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer - BioNTech COVID-19 vaccine United States, December 14-23, 2020. MM WR Morb Mort al Wkly. Rep. 2021; 70: 4651. doi: 10.15585/mmwr.mm7002e12. doi: 10.4168/aair.2021.13.4.526.
[7]	Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021; 384: 403-416. doi: 10.1056/NEJMoa2035389.
[8]	Kounis NG, Koniari I, de Gregorio C, et al. Allergic reactionsto current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations. Vaccines (Basel). 2021; 9: 221. doi: 10.3390/vaccines9030221.
[9]	Frantz, R.; Huang, S.; Are, A.; Motaparthi, K. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina 2021, 57, 895. https://doi.org/10.3390/ medicina57090895.
[10]	Burlando M, Herzum A, Micalizzi C, Cozzani E, Parodi A. Cutaneous reactions to COVID-19 vaccine at the Dermatology Primary Care. Immun Inflamm Dis. 2021; 1-7. doi: 10.1002/iid3.568.
[11]	Su JR, Haber P, Ng CS, et al. Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999-2017. Vaccine. 2020; 38 (7): 1746-1752. doi: 10.1016/j.vaccine.2019.12.028.
[12]	Lospinoso K, Nichols CS, Malachowski SJ, Mochel MC, Nutan F. A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine. JAAD Case Rep. 2021; 13: 134-137. doi: 10.1016/j.jdcr.2021.05.010.
[13]	Ghimire K, Adhikari N. Morbilliform rashes in a patient with COVID-19 infection: a case report. JNMA J Nepal Med Assoc. 2021; 59: 399-401. doi: 10.31729/jnma.5128.
[14]	Cyrenne BM, Al-Mohammedi F, DeKoven JG, Alhusayen R. Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine. J Eur Acad Dermatol Venereol.2021; 13: 546. doi: 10.1111/jdv.17342 20.D.
[15]	Berry CT, Eliliwi M, Gallagher S, et al. Cutaneous small vessel vasculitis following single-dose Janssen Ad26.COV2.S vaccination. JAAD Case Rep. 2021; 15: 11-14. doi: 10.1016/j.jdcr.2021.07.002.

Cite This Article

Plain Text BibTeX RIS

APA Style

Daniel Pacheco Ambriz, Lorena Lizbeth Félix Guerrero, Giselle Anahí Olivas Cárdenas, Alicia Pastora Amarillas Villalvazo, Lorena Diaz Amezquita. (2022). Stevens-Johnson Syndrome Associated to the Administration of Janssen AD26.COV2.S COVID-19 Vaccine in Tijuana, Baja California, México, a Case Report. International Journal of Clinical Oral and Maxillofacial Surgery, 8(1), 1-4. https://doi.org/10.11648/j.ijcoms.20220801.11

Copy | Download

ACS Style

Daniel Pacheco Ambriz; Lorena Lizbeth Félix Guerrero; Giselle Anahí Olivas Cárdenas; Alicia Pastora Amarillas Villalvazo; Lorena Diaz Amezquita. Stevens-Johnson Syndrome Associated to the Administration of Janssen AD26.COV2.S COVID-19 Vaccine in Tijuana, Baja California, México, a Case Report. Int. J. Clin. Oral Maxillofac. Surg. 2022, 8(1), 1-4. doi: 10.11648/j.ijcoms.20220801.11

Copy | Download

AMA Style

Daniel Pacheco Ambriz, Lorena Lizbeth Félix Guerrero, Giselle Anahí Olivas Cárdenas, Alicia Pastora Amarillas Villalvazo, Lorena Diaz Amezquita. Stevens-Johnson Syndrome Associated to the Administration of Janssen AD26.COV2.S COVID-19 Vaccine in Tijuana, Baja California, México, a Case Report. Int J Clin Oral Maxillofac Surg. 2022;8(1):1-4. doi: 10.11648/j.ijcoms.20220801.11

Copy | Download

@article{10.11648/j.ijcoms.20220801.11,
  author = {Daniel Pacheco Ambriz and Lorena Lizbeth Félix Guerrero and Giselle Anahí Olivas Cárdenas and Alicia Pastora Amarillas Villalvazo and Lorena Diaz Amezquita},
  title = {Stevens-Johnson Syndrome Associated to the Administration of Janssen AD26.COV2.S COVID-19 Vaccine in Tijuana, Baja California, México, a Case Report},
  journal = {International Journal of Clinical Oral and Maxillofacial Surgery},
  volume = {8},
  number = {1},
  pages = {1-4},
  doi = {10.11648/j.ijcoms.20220801.11},
  url = {https://doi.org/10.11648/j.ijcoms.20220801.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcoms.20220801.11},
  abstract = {Background: Stevens-Johnson syndrome and toxic epidermal necrolysis are rare pathologies characterized by mucocutaneous involvement, considered as late hypersensitivity mainly associated with drugs. Other less frequent causes include infections, vaccines, systemic diseases and botanical medicine. COVID-19 vaccines can cause adverse reactions mainly from vaccine- induced immune responses. We present a clinical case of a patient with Stevens-Johnson syndrome diagnose, without no history of factors related to this pathology, except for the use of Ad26.COV2.S (Janssen/Johnson & Johnson) vaccine Clinical case: A 20 years old male patient with clinical and histopathological characteristics compatible with Stevens Johnson syndrome and whose background history was the application of the Ad26.COV2.S vaccine (Janssen / Johnson & Johnson) 11 days prior to the start of the disease. At arrival at the emergency room he got a dermatologic consult who started treatment with metilprednisolone 1gr intravenously, Aciclovir 200mg orally and topic fluocinolone. He was hospitalized in charge of dermatology presenting improvement deciding outpatient treatment. Five days after his hospital discharge, at dermatology external consultation he´s found with overall improvement and fewer dermic lesions. Conclusions: At this time we didn’t find a case where they reported Stevens-Johnson syndrome associated to Ad26.COV2.S vaccine. Although the information regarding the adverse effects of the new vaccines against COVID-19 is still limited, there is the possibility of a direct association between the Ad26.COV2.S vaccine and a Stevens Johnson Syndrome.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Stevens-Johnson Syndrome Associated to the Administration of Janssen AD26.COV2.S COVID-19 Vaccine in Tijuana, Baja California, México, a Case Report
AU  - Daniel Pacheco Ambriz
AU  - Lorena Lizbeth Félix Guerrero
AU  - Giselle Anahí Olivas Cárdenas
AU  - Alicia Pastora Amarillas Villalvazo
AU  - Lorena Diaz Amezquita
Y1  - 2022/01/24
PY  - 2022
N1  - https://doi.org/10.11648/j.ijcoms.20220801.11
DO  - 10.11648/j.ijcoms.20220801.11
T2  - International Journal of Clinical Oral and Maxillofacial Surgery
JF  - International Journal of Clinical Oral and Maxillofacial Surgery
JO  - International Journal of Clinical Oral and Maxillofacial Surgery
SP  - 1
EP  - 4
PB  - Science Publishing Group
SN  - 2472-1344
UR  - https://doi.org/10.11648/j.ijcoms.20220801.11
AB  - Background: Stevens-Johnson syndrome and toxic epidermal necrolysis are rare pathologies characterized by mucocutaneous involvement, considered as late hypersensitivity mainly associated with drugs. Other less frequent causes include infections, vaccines, systemic diseases and botanical medicine. COVID-19 vaccines can cause adverse reactions mainly from vaccine- induced immune responses. We present a clinical case of a patient with Stevens-Johnson syndrome diagnose, without no history of factors related to this pathology, except for the use of Ad26.COV2.S (Janssen/Johnson & Johnson) vaccine Clinical case: A 20 years old male patient with clinical and histopathological characteristics compatible with Stevens Johnson syndrome and whose background history was the application of the Ad26.COV2.S vaccine (Janssen / Johnson & Johnson) 11 days prior to the start of the disease. At arrival at the emergency room he got a dermatologic consult who started treatment with metilprednisolone 1gr intravenously, Aciclovir 200mg orally and topic fluocinolone. He was hospitalized in charge of dermatology presenting improvement deciding outpatient treatment. Five days after his hospital discharge, at dermatology external consultation he´s found with overall improvement and fewer dermic lesions. Conclusions: At this time we didn’t find a case where they reported Stevens-Johnson syndrome associated to Ad26.COV2.S vaccine. Although the information regarding the adverse effects of the new vaccines against COVID-19 is still limited, there is the possibility of a direct association between the Ad26.COV2.S vaccine and a Stevens Johnson Syndrome.
VL  - 8
IS  - 1
ER  -

Copy | Download

Author Information

Daniel Pacheco Ambriz

Emergent Care Unit, Regional General Hospital #20 IMSS, Tijuana, México
Lorena Lizbeth Félix Guerrero

Emergen Care Unit Rotation, Univerdsidad Autonoma de Baja California, Regional General Hospital #20 Instituto Mexicano del Seguro Social (IMSS), Tijuana, México
Giselle Anahí Olivas Cárdenas

Emergen Care Unit Rotation, Univerdsidad Autonoma de Baja California, Regional General Hospital #20 Instituto Mexicano del Seguro Social (IMSS), Tijuana, México
Alicia Pastora Amarillas Villalvazo

Dermatology Department, Regional General Hospital #20 Instituto Mexicano del Seguro Social (IMSS), Tijuana, México
Lorena Diaz Amezquita

Pathology Department, Regional General Hospital #1 Instituto Mexicano del Seguro Social (IMSS), Tijuana, Mexico

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Daniel Pacheco Ambriz, Lorena Lizbeth Félix Guerrero, Giselle Anahí Olivas Cárdenas, Alicia Pastora Amarillas Villalvazo, Lorena Diaz Amezquita. (2022). Stevens-Johnson Syndrome Associated to the Administration of Janssen AD26.COV2.S COVID-19 Vaccine in Tijuana, Baja California, México, a Case Report. International Journal of Clinical Oral and Maxillofacial Surgery, 8(1), 1-4. https://doi.org/10.11648/j.ijcoms.20220801.11

Copy | Download

ACS Style

Daniel Pacheco Ambriz; Lorena Lizbeth Félix Guerrero; Giselle Anahí Olivas Cárdenas; Alicia Pastora Amarillas Villalvazo; Lorena Diaz Amezquita. Stevens-Johnson Syndrome Associated to the Administration of Janssen AD26.COV2.S COVID-19 Vaccine in Tijuana, Baja California, México, a Case Report. Int. J. Clin. Oral Maxillofac. Surg. 2022, 8(1), 1-4. doi: 10.11648/j.ijcoms.20220801.11

Copy | Download

AMA Style

Daniel Pacheco Ambriz, Lorena Lizbeth Félix Guerrero, Giselle Anahí Olivas Cárdenas, Alicia Pastora Amarillas Villalvazo, Lorena Diaz Amezquita. Stevens-Johnson Syndrome Associated to the Administration of Janssen AD26.COV2.S COVID-19 Vaccine in Tijuana, Baja California, México, a Case Report. Int J Clin Oral Maxillofac Surg. 2022;8(1):1-4. doi: 10.11648/j.ijcoms.20220801.11

Copy | Download

@article{10.11648/j.ijcoms.20220801.11,
  author = {Daniel Pacheco Ambriz and Lorena Lizbeth Félix Guerrero and Giselle Anahí Olivas Cárdenas and Alicia Pastora Amarillas Villalvazo and Lorena Diaz Amezquita},
  title = {Stevens-Johnson Syndrome Associated to the Administration of Janssen AD26.COV2.S COVID-19 Vaccine in Tijuana, Baja California, México, a Case Report},
  journal = {International Journal of Clinical Oral and Maxillofacial Surgery},
  volume = {8},
  number = {1},
  pages = {1-4},
  doi = {10.11648/j.ijcoms.20220801.11},
  url = {https://doi.org/10.11648/j.ijcoms.20220801.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcoms.20220801.11},
  abstract = {Background: Stevens-Johnson syndrome and toxic epidermal necrolysis are rare pathologies characterized by mucocutaneous involvement, considered as late hypersensitivity mainly associated with drugs. Other less frequent causes include infections, vaccines, systemic diseases and botanical medicine. COVID-19 vaccines can cause adverse reactions mainly from vaccine- induced immune responses. We present a clinical case of a patient with Stevens-Johnson syndrome diagnose, without no history of factors related to this pathology, except for the use of Ad26.COV2.S (Janssen/Johnson & Johnson) vaccine Clinical case: A 20 years old male patient with clinical and histopathological characteristics compatible with Stevens Johnson syndrome and whose background history was the application of the Ad26.COV2.S vaccine (Janssen / Johnson & Johnson) 11 days prior to the start of the disease. At arrival at the emergency room he got a dermatologic consult who started treatment with metilprednisolone 1gr intravenously, Aciclovir 200mg orally and topic fluocinolone. He was hospitalized in charge of dermatology presenting improvement deciding outpatient treatment. Five days after his hospital discharge, at dermatology external consultation he´s found with overall improvement and fewer dermic lesions. Conclusions: At this time we didn’t find a case where they reported Stevens-Johnson syndrome associated to Ad26.COV2.S vaccine. Although the information regarding the adverse effects of the new vaccines against COVID-19 is still limited, there is the possibility of a direct association between the Ad26.COV2.S vaccine and a Stevens Johnson Syndrome.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Stevens-Johnson Syndrome Associated to the Administration of Janssen AD26.COV2.S COVID-19 Vaccine in Tijuana, Baja California, México, a Case Report
AU  - Daniel Pacheco Ambriz
AU  - Lorena Lizbeth Félix Guerrero
AU  - Giselle Anahí Olivas Cárdenas
AU  - Alicia Pastora Amarillas Villalvazo
AU  - Lorena Diaz Amezquita
Y1  - 2022/01/24
PY  - 2022
N1  - https://doi.org/10.11648/j.ijcoms.20220801.11
DO  - 10.11648/j.ijcoms.20220801.11
T2  - International Journal of Clinical Oral and Maxillofacial Surgery
JF  - International Journal of Clinical Oral and Maxillofacial Surgery
JO  - International Journal of Clinical Oral and Maxillofacial Surgery
SP  - 1
EP  - 4
PB  - Science Publishing Group
SN  - 2472-1344
UR  - https://doi.org/10.11648/j.ijcoms.20220801.11
AB  - Background: Stevens-Johnson syndrome and toxic epidermal necrolysis are rare pathologies characterized by mucocutaneous involvement, considered as late hypersensitivity mainly associated with drugs. Other less frequent causes include infections, vaccines, systemic diseases and botanical medicine. COVID-19 vaccines can cause adverse reactions mainly from vaccine- induced immune responses. We present a clinical case of a patient with Stevens-Johnson syndrome diagnose, without no history of factors related to this pathology, except for the use of Ad26.COV2.S (Janssen/Johnson & Johnson) vaccine Clinical case: A 20 years old male patient with clinical and histopathological characteristics compatible with Stevens Johnson syndrome and whose background history was the application of the Ad26.COV2.S vaccine (Janssen / Johnson & Johnson) 11 days prior to the start of the disease. At arrival at the emergency room he got a dermatologic consult who started treatment with metilprednisolone 1gr intravenously, Aciclovir 200mg orally and topic fluocinolone. He was hospitalized in charge of dermatology presenting improvement deciding outpatient treatment. Five days after his hospital discharge, at dermatology external consultation he´s found with overall improvement and fewer dermic lesions. Conclusions: At this time we didn’t find a case where they reported Stevens-Johnson syndrome associated to Ad26.COV2.S vaccine. Although the information regarding the adverse effects of the new vaccines against COVID-19 is still limited, there is the possibility of a direct association between the Ad26.COV2.S vaccine and a Stevens Johnson Syndrome.
VL  - 8
IS  - 1
ER  -

Copy | Download